LifeMine Therapeutics and GSK enter drug discovery and development alliance
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
The collaboration will utilize Avatar-Rx, LifeMine’s proprietary genomically-enabled drug discovery platform to access evolutionarily derived lead small molecules
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
Kiran will be joining RSE's current Fellowship of around 1,700 Fellows who are recognized as being some of the greatest thinkers, researchers and practitioners working in or with Scotland
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
The collaboration leverages Insilico's end-to-end AI-driven Pharma.AI platform to discover novel small molecule drug candidates for multiple targets, along with EQRx's innovative business model to accelerate drug development and patient access to novel medicines at affordable prices
Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
The company is Series A funded with US $ 7 million in funding so far
The investment will improve equipment efficiency and increase safety standards at its Lestrem site
As part of this partnership, Huma and AstraZeneca will launch Software as a Medical Device (SaMD) companion apps targeted at several therapeutic areas and will partner to help accelerate the adoption of decentralized clinical trials
Data to establish the safety profile and human dose of vaccine candidate
Subscribe To Our Newsletter & Stay Updated